Ligand Pharmaceuticals (LGND) Insider Trading & Ownership $111.56 -0.24 (-0.21%) (As of 11/20/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Ligand Pharmaceuticals (NASDAQ:LGND) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.90%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$243,475.00Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$7.56 M Get LGND Insider Trade Alerts Want to know when executives and insiders are buying or selling Ligand Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address LGND Insider Buying and Selling by Quarter Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Ligand Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/23/2024Andrew ReardonInsiderSell2,000$99.60$199,200.00 9/23/2024Matthew E KorenbergCOOSell9,772$101.22$989,121.84 9/20/2024Matthew E KorenbergCOOSell6,275$104.10$653,227.50 9/20/2024Octavio EspinozaCFOSell1,275$103.94$132,523.50 8/28/2024Andrew ReardonInsiderSell1,500$106.39$159,585.00 8/26/2024Matthew E KorenbergCOOSell11,389$105.61$1,202,792.29 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 8/22/2024Matthew E KorenbergCOOSell1,157$105.54$122,109.78 8/9/2024Matthew E KorenbergCOOSell18,245$98.50$1,797,132.50 8/8/2024Todd C DavisCEOBuy2,500$97.39$243,475.00 5/17/2024Octavio EspinozaCFOSell5,156$86.66$446,818.96 5/15/2024Octavio EspinozaCFOSell5,873$86.01$505,136.73 5/13/2024Matthew E KorenbergInsiderSell3,440$84.54$290,817.60 5/9/2024Andrew ReardonInsiderSell10,000$83.04$830,400.00 5/9/2024Nancy Ryan GrayDirectorSell934$83.20$77,708.80 3/5/2024Stephen L SabbaDirectorSell1,893$74.30$140,649.90 2/28/2024Octavio EspinozaCFOSell140$88.46$12,384.40 (Data available from 1/1/2013 forward) LGND Insider Trading Activity - Frequently Asked Questions Who is on Ligand Pharmaceuticals's Insider Roster? The list of insiders at Ligand Pharmaceuticals includes Andrew Reardon, John L Higgins, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Nancy Ryan Gray, Octavio Espinoza, Stephen L Sabba, and Todd C Davis. Learn more on insiders at LGND. What percentage of Ligand Pharmaceuticals stock is owned by insiders? 5.90% of Ligand Pharmaceuticals stock is owned by insiders. Learn more on LGND's insider holdings. Which Ligand Pharmaceuticals insiders have been buying company stock? The following insider purchased LGND shares in the last 24 months: Todd C Davis ($480,995.00). How much insider buying is happening at Ligand Pharmaceuticals? Insiders have purchased a total of 6,500 LGND shares in the last 24 months for a total of $480,995.00 bought. Which Ligand Pharmaceuticals insiders have been selling company stock? The following insiders have sold LGND shares in the last 24 months: Andrew Reardon ($1,210,161.00), John L Higgins ($618,700.00), John W Kozarich ($833,673.28), Matthew E Korenberg ($5,055,201.51), Nancy Ryan Gray ($77,708.80), Octavio Espinoza ($1,096,863.59), and Stephen L Sabba ($634,898.94). How much insider selling is happening at Ligand Pharmaceuticals? Insiders have sold a total of 106,609 Ligand Pharmaceuticals shares in the last 24 months for a total of $9,527,207.12 sold. Ligand Pharmaceuticals Key ExecutivesMr. Matthew E. Korenberg (Age 49)President & COO Compensation: $831.77k5 recent tradesMr. Octavio Espinoza (Age 53)Chief Financial Officer Compensation: $613.59k1 recent tradesMr. Andrew T. Reardon J.D. (Age 49)Chief Legal Officer & Secretary Compensation: $614.87kMr. Scott M. Plesha (Age 59)Chief Executive Officer Mr. Paul J. HaddenSenior Vice President of Investments & Business DevelopmentSimon LatimerHead of Investor RelationsMr. Todd PettingillDirector of Corporate DevelopmentMs. Audrey Warfield-GrahamChief People OfficerDr. Keith MarschkeSenior Vice President of Biology & Scientific AffairsDr. Vincent D. Antle (Age 55)Senior Vice President of Technical Operations & QA - Capitsol More Insider Trading Tools from MarketBeat Related Companies NRIX Insider Trading TVTX Insider Trading PRAX Insider Trading ARCT Insider Trading CMPS Insider Trading STTK Insider Trading RGEN Insider Trading MDGL Insider Trading HALO Insider Trading IONS Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:LGND) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide vic...Wide Moat Research | SponsoredThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
